Kornimate/medical-research-clean huggingface dataset:
study of genetic differences in people with depression

Conditions: Depressive Disorder, Major

Summary: the purpose of this study is to identify genes involved in depression. specifically, the investigators will analyze some genes that may be related to whether or not a person responds to antidepressant medication. this project is part of basic scientific research to increase understanding of the role of genetic influences in psychological and mental processes involved in the response to treatment for depression.


Eligibility criteria:
inclusion criteria: * history of unipolar major depression * control subjects must be healthy normal adults exclusion criteria: * subjects with mood symptoms that are not severe enough to qualify for mdd * subjects with any active medical illness that may be related to ongoing mood disorder * normal subjects must be free from: a psychiatric diagnosis, substance abuse, a history of seizure disorder, and any serious medical illness

Keywords: depression genetic gene antidepressant research
navigation with x3 vs non-navigation with x3 study

Conditions: Degenerative Joint Disease

Summary: the purpose of this study is to compare the effect of the large head in tha with a navigation system and without a navigation system.


Eligibility criteria:
inclusion criteria: 1. patient who is a candidate for a primary total hip arthroplasty (tha) with cementless acetabular and femoral components. 2. patient who has a diagnosis of degenerative joint disease and no bacterial infectious disease. 3. patient who is age 20 or over. 4. patient who signed an institutional review board (irb)-approved, study specific informed patient consent form. 5. patient who is willing to and able to comply with postoperative scheduled evaluations. exclusion criteria: 1. patient who has a bacterial infectious disease or has a high risk of a bacterial infection. 2. patient who requires revision surgery of a previously implanted total hip arthroplasty. 3. patient who is morbidly obese, defined as having a body mass index (bmi) \> 45. 4. patient who is or may be pregnant female. 5. patient who has neuromuscular or neurosensory deficiency, which limits ability to evaluate the safety and efficacy of the device. 6. patient with diagnosed systemic disease (i.e. paget's disease, renal osteodystrophy). 7. patient who is immunologically suppressed or receiving chronic steroids. 8. patient who is judged ineligible with specific reason by primary doctor.
a clinical investigation with epaderm® cream

Conditions: Eczema; Psoriasis; Dry Skin; Eczema

Summary: this investigation is designed as a prospective, non-randomised, single arm clinical investigation. data is collected from approximately 120 evaluable subjects, divided into three groups of approximately 40 subjects; infants (0-36 months old), children (3-18 years old) and adults (\>18 years old), with the following indications: eczema, psoriasis and other dry skin conditions. each subject will be followed during 4 weeks treatment, with a visit at baseline (visit 1), at 2 weeks (visit 2) and at 4 weeks (visit 3) treatment.

primary endpoint skin hydration after treatment with epaderm cream up to 4 weeks, evaluated by the subject using a questionnaire. secondary endpoints 1. skin hydration after treatment with epaderm cream up to 4 weeks, evaluated by investigator/nurse using a questionnaire. 2. skin hydration after treatment with epaderm cream up to 4 weeks, using a non-invasive device moisturemeterepid. 3. investigator/nurse evaluation of skin softness after 2 and 4 weeks treatment, using a questionnaire. 4. subject evaluation of skin softness after 2 and 4 weeks treatment, using a questionnaire. 5. investigator/nurse evaluation regarding: * clinical signs/conditions of the affected skin and changes thereof * did the product prolong the relapse period for flares? 6. subject evaluation regarding: * did you use epaderm cream according to prescription? * comfort during treatment * time of onset of effect * did the product have the expected effect * overall impression * was the investigational device used as a skin cleanser? 7. concomitant and previous medication and treatment 8. number of adverse device effects (ades) related to the use of epaderm cream during the investigation

Eligibility criteria:
inclusion criteria: 1. subjects suitable for treatment with epaderm cream, as deemed by the investigator and according to intended use (eczema, psoriasis and other dry skin conditions). 2. subject or subject's legal representative must be able to read and sign the patient information and consent form. exclusion criteria: 1. known allergy/hypersensitivity to any of the components of epaderm cream. 2. subject not suitable for the investigation according to the investigator's judgement. 3. subject participating in other ongoing similar clinical studies or other clinical studies which could interfere with this investigation, as judged by the investigator. 4. subject previously enrolled in the current clinical investigation.
a reliability and validity study: urdu version of rivermead extended activities of daily life

Conditions: Neurological Disorder

Summary: the goal of this study is to translate and culturally adapt rivermead extended activities of daily life into the urdu language and to evaluate its reliability and validity in the pakistani neurological rehabilitation population. also assess its correlation with memory and concentration test, the barthel index, and the index of french activities.

as per the preceding commendation, rivermead extended activities of daily life will be deciphered into the urdu dialect from its english adaptation and adjusted socially in pakistan. among the neurological rehabilitation population, rivermead extended activities of daily life will be distributed in 100 patients enrolled by comfort inspecting strategy beneath the pre-defined incorporation and avoidance criteria after marking assent shapes. for testing inter-observer unwavering quality and intra-observer unwavering quality of rivermead extended activities of daily life, memory and concentration test, index of french activities, and barthel index surveys will be managed by spectator, on the same day, with a time interval of 2 hours between 1st and 2nd readings. as for the 3rd readings, it will be carried out after seven days by the first observer, for intra-observer appraisal. statistical package of social sciences computer program has been utilized for information passage and examination. inner consistency will be analyzed with cronbach alpha esteem. test-retest unwavering quality will be surveyed by utilizing an intra-class relationship coefficient. the rivermead extended activities of daily life will be assessed for content validity, construct validity, criterion validity, and responsiveness.

Eligibility criteria:
inclusion criteria: * patients from rehabilitation centers mainly outpatients; with more or severe impairments due to neurological /neuro-muscular diseases. * patient should be in a stable state unlikely to change over 2- weeks. * patient should score 18/28 short orientation-memory-concentration test; indicating a reasonable cognitive and communicative ability. exclusion criteria: * people not suffering from any neurological impairment. * scorning less than 18/28 on short orientation-memory-concentration test.

Keywords: rivermead extended activities of daily life urdu version reliability validity neurological disorder
pharmacopuncture therapy for cervical disc herniation: a pilot study

Conditions: Cervical Disc Herniation

Summary: this is pilot study for a 3-arm parallel pragmatic randomized controlled trial that will compare pharmacopuncture therapy, acupunture therapy and physical therapy, medication(prn) for cervical disc herniation.

this is a pragmatic rct, so the physicians will choose the type and volume of pharmacopuncture, the type and number of acupuncture and the type and time of physical therapy according to participants' conditions, respectively.

Eligibility criteria:
inclusion criteria: 1. symptoms of cervical disc herniation for less than 12 months 2. numeric rating scale (nrs) of neck pain is more than 5 3. symptoms of neuromuscular disease in one or both upper limbs (pain, pull, numbness, sensory abnormalities, motor abnormalities) 4. discrimination findings above protusion, which can explain clinical symptoms on cervical spine mri or ct 5. 19-69 years old 6. participants who agreed and wrote informed consents exclusion criteria: 1. case of being diagnosed with a specific serious disease that may cause neck pain(migration of cancer reaching to spine, acute fracture of spine, spine dislocation) 2. progressive neurologic deficits or severe neurologic deficits 3. cause of pain due to soft tissue disease, not the spine(cancer, fibromyalgia, ra, goat, or etc.) 4. other chronic diseases(stroke, mi, kidney disease, diabetic neuropathy, dimentia, epilepsy, or etc.) that may interfere with the interpretation of therapeutic effects or outcomes 5. participants taking steroid, immunosuppressant, psychotropic medication, or taking other drugs that may affect outcomes 6. inappropriate or unsafe pharmacopuncture therapy; hemorrhagic disease, taking anticoagulant drug, or severe diabetes patients who are likely to be infected 7. participants who took nsaids or pharmacopuncture, acupuncture, physical therapy within 1 week 8. pregnant, planning to get pregnant or lactating women 9. participants who had undergone cervical surgery within 3 months 10. participants who had participated in other clinical trial within 1 month, had participated in other study within 6 months from the date of selection, or have plan for participation in other trial during follow up period of this trial 11. participants who can not write informed consent 12. participants who is difficult to participate in the trial according to investigator's decision
acute effects of ginger extract consumption on risk markers of cardiovascular disease

Conditions: Cardiovascular Disease

Summary: the primary aim of the study was to investigate the acute effect of ginger drink consumption on the risk markers of cardiovascular disease.

a randomized, single-blind human intervention study involving 22 healthy male volunteers was designed to investigate the acute effects of ginger drink consumption on risk markers of cardiovascular disease (cvd). the primary outcome measure is reduction in blood pressure while the secondary outcome measures are improvement in flow mediated dilatation (fmd) and changes in plasma biochemical profile parameters related to cvd. participants were given 300 ml of ginger extract or water (placebo) with breakfast, followed by a lunch at 2 hours on two visits separated by 2 weeks. blood and urine samples were collected at regular intervals as well as blood pressure measurement done during the two visits. vascular function was measured by flow mediated dilatation (fmd) and pulse wave velocity (pwv) at baseline, 2 and 4 hours after the the consumption of the study drink and placebo. the blood and urine samples were analysed for changes in lipid profile and other markers of cvd.

Eligibility criteria:
inclusion criteria: * apparently healthy males, * age (30 - 65) years, * not diabetic or plasma glucose \> 7 or on anti-diabetic drugs and not on anti- hypertensive drugs. * subjects \< 10% risk of cardiovascular disease exclusion criteria: * women, * men younger than 30 years and older that 65 years, * men who are sick or on anti-diabetic and anti-hypertensive drugs. * men who have history of heart attack or stroke within the last 12 months * men who are on lipids lowering drugs

Keywords: ginger blood pressure flow mediated dilatation
zyprexa® relprevv™ patient care program

Conditions: Schizophrenia

Summary: the goal of the zyprexa relprevv patient care program is to mitigate the risk of negative outcomes associated with zyprexa relprevv post-injection delirium/sedation syndrome (pdss).

the goal of the zyprexa relprevv patient care program is to mitigate the risk of negative outcomes associated with zyprexa relprevv post-injection delirium/sedation syndrome (pdss) by: 1. ensuring zyprexa relprevv is prescribed only by certified prescribers, dispensed only by certified dispensers, and dispensed for use only in certified healthcare facilities with ready access to emergency response services, and dispensed for use only with documentation of safe use conditions; 2. informing health care providers and patients about the risks and the need for continuous observation of patients for at least 3 hours in certified healthcare facilities; and 3. establishing long-term safety and safe use of zyprexa relprevv through periodic monitoring for the risk of pdss events and by enrolling all patients who receive zyprexa relprevv in the zyprexa relprevv patient care program registry.

Eligibility criteria:
inclusion criteria: * any patients receiving zyprexa relprevv enrolled in zyprexa relprevv patient care program exclusion criteria: * any patient not receiving zyprexa relprevv
cerebral oximetry with near-infrared spectroscopy and negative postoperative behavioral changes in pediatric surgery

Conditions: Cognitive Dysfunction

Summary: the main objective of the present study was to evaluate whether cerebral oxygen saturation is associated with an increase of npobc in pediatric patients undergoing major surgery.

this prospective and observational study involved consecutive patients aged between 2 and 12 years undergoing a major surgery using general anesthesia. cerebral oxygen saturation, non-invasive arterial pressure, pulse oximetry, and heart rate were recorded at the following stages of the surgical intervention: baseline, induction, intubation, surgical incision, end of surgery, and extubation. preoperative anxiety was evaluated by using the modified yale preoperative anxiety scale, and npobc was determined by using the post-hospital behaviour questionnaire on 7th and 28th postoperative days. a logistic regression was created to identify factors associated with the development of npobc

Eligibility criteria:
inclusion criteria: * patients aged between 2 and 12 years undergoing major surgery using general anesthesia. exclusion criteria: * children aged below 2 or over 12. * neuropsychiatric disorder, or undergoing an emergency surgery.

Keywords: postoperative behavioral changes
mind (management of traumatic brain injury diagnosis)

Conditions: Brain Injury

Summary: procure blood specimens from individuals presenting to the emergency department with suspected brain injury.


Eligibility criteria:
inclusion criteria: * informed consent form signed * 18 years of age or older * for women of child-bearing age: not known to be pregnant and * head trauma within 6 hours of ed presentation with glasgow coma scores from 3-8 (severe injury), 9-13 (moderate injury), or 14-15 (mild injury); or * head trauma within 6 hours of ed presentation with glasgow coma score of 15; or * bone fracture or poly-traumas, both with no head trauma exclusion criteria: * known pre-existing neurological condition that causes observed symptoms * recent history of head injury or seizures (within 1 year of current ed presentation) * prisoner

Keywords: brain injury
study on the incidence of adrenal insufficiency after surgery in primary aldosteronism patients concurrent with or without autonomous cortisol secretion

Conditions: Primary Aldosteronism; Autonomous Cortisol Secretion; Adrenal Insufficiency

Summary: to evaluate the incidence of adrenal insufficiency after surgery in primary aldosteronism patients concurrent with or without autonomous cortisol secretion.

this study is a prospective, single-center research. primary aldosteronism patients concurrent with or without autonomous cortisol secretion who underwent adrenalectomy and completed the acth stimulation test will be included. to evaluate the incidence of adrenal insufficiency after surgery in these patients.

Eligibility criteria:
inclusion criteria: * pa conccurent with or without autonomous cortisol secretion * complete adrenalectomy * complete acth stimulation test on the one day after surgery * complete follow-up at 6，12 months after surgery exclusion criteria: * patients underwent partial adrenalectomy * suspicion of familial hyperaldosteronism or liddle syndrome. \[i.e., age \<20 years, hypertension and hypokalemia, or with family history\] * suspicion of pheochromocytoma or adrenal carcinoma. * congestive heart failure with new york heart association (nyha) functional classification iii or iv; history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; severe anemia (hb\ 3 times the upper limit of normal, or estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2); systemic inflammatory response syndrome (sirs); uncontrolled diabetes (fbg≥13.3 mmol/l); obesity (bmi≥35 kg/m2) or underweight (bmi≤18 kg/m2); untreated aneurysm; other comorbidity potentially interfering with treatment; * patients with actively malignant tumor. * long- term use of glucocorticoids. * suspected pbmah or ppnad;

Keywords: primary aldosteronism autonomous cortisol secretion adrenal insufficiency acth stimulation test
conversion from fast acting oral opioids to abstral®

Conditions: Pain

Summary: the purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (sl) fentanyl (abstral) for treatment of breakthrough cancer pain (btcp).

the study aims to show that in the advanced stage of cancer the individual patient already on high doses of btcp medication will benefit from starting treatment on a higher first dose of sl fentanyl thus reducing the number of dosing steps with insufficient pain relief.

Eligibility criteria:
inclusion criteria: * signed informed consent obtained. * 18 years or older, of both genders. * opioid tolerant patients * estimated frequency of btcp 0.5-4 times a day. exclusion criteria: * treatment with sl fentanyl within two weeks prior to screening. * recent or planned therapy that would alter pain or responses to analgesics. * treatment with monoamine oxidase inhibitor \< 14 days before or concurrent with sl fentanyl treatment. * significantly reduced liver and/or kidney function. * significant prior history of substance abuse. * pregnancy, breast feeding or woman of childbearing potential not using adequate birth control.

Keywords: sublingual fentanyl titration conversion breakthrough cancer pain pain intensity difference pid edmonton symptom assessment system esas
safety and immunogenicity study of tetanus, diphtheria and acellular pertussis (tdap) vaccine

Conditions: Tetanus; Diphtheria; Whooping Cough

Summary: the purpose of this study is to evaluate safety of gc3111 and to describe immunogenicity of a single dose of gc3111 versus boostrix® vaccine among healthy adults in 19 to \<65 years of age.

to evaluate immunogenicity of gc3111 as tetanus, diphtheria and acellular pertussis (tdap) vaccine in healthy adults. to evaluate safety (solicited adverse events) of gc3111 in healthy adults.

Eligibility criteria:
inclusion criteria: * healthy adults aged between 19 and 64 years at the time of vaccination * informed consent and assent forms have been signed and dated exclusion criteria: * known or suspected receipt of any tdap vaccine * subject is pregnant, or lactating, or of child bearing potential without using an effective method of contraception or not practicing abstinence * receipt of any vaccine within 30 days before receiving study vaccine * any condition that, in the opinion of the investigator, might interfere with the ability to comply with trial procedures.
a study of mucosal sparing proton beam therapy (pbt) in resected oropharyngeal tumors

Conditions: Oropharyngeal Tumor

Summary: this study is an observational study evaluating the clinical outcomes of mucosal sparing proton beam therapy (pbt) after resection of favorable risk oropharyngeal cancer patients. subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this study. once consent has been obtained baseline adverse event and quality of life (qol) data will be collected and subjects will undergo adjuvant pbt and follow-up at 3 months, 12 months, and 24 months. no study-specific visits or evaluations will be required. patients will be evaluated according to the physician's standard practice and discretion. patient data will be drawn from the patients' medical records and reported by means of a web-based electronic data collection (edc) system. patients will be considered "on study" until 24 months of observation has occurred, withdrawal of consent, lost to follow-up, or study closure.


Eligibility criteria:
inclusion criteria: * resection of oropharyngeal tumor by transoral surgery using frozen section margin analysis resulting in a negative margin resection * no extensive perineural invasion after review by head and neck pathologist * no lymphovascular invasion after review by head and neck pathologist * pathologic stage t1-2 n1-3 m0 disease exclusion criteria: * t3 or t4 primary stage disease * prior radiation therapy to the head and neck

Keywords: proton
the effect of self-efficacy promoting program using computer game on proteinuria in thai children with nephrotic syndrome

Conditions: Nephrotic Syndrome in Children

Summary: nephrotic syndrome is a medical condition where the kidneys release substantial amounts of protein into the urine, resulting in various issues such as tissue swelling and an increased susceptibility to infections. emphasizing the importance of adequate nutrition and symptom monitoring is crucial in managing urine protein levels and mitigating associated complications. the purpose of this study was to boost self-efficacy through a computer game-based program, aiding pediatric patients with nephrotic syndrome in the adoption of healthy eating habits and efficient management of urine protein levels.

this study was quasi-experimental research. two group pre-test post-test with repeated measures design. forty school-age children diagnosed with nephrotic syndrome were randomly allocated into two groups, with the participants distributed between an experimental group and a control group, each comprising 20 individuals. the experimental group underwent a program that aimed to enhance self-efficacy through computer games for a duration of 5 weeks, whereas the control group received regular nursing care. information was gathered through personal record forms, urine protein assessments with test strips, dietary behavior surveys for school-age children with nephrotic symptoms, and self-efficacy surveys related to dietary behavior within the same group. the data underwent analysis using repeated measures analysis of variance. statistical significance was defined as p \< .05.

Eligibility criteria:
inclusion criteria: * confirmation of nephrotic syndrome diagnosis by a physician and continuous hospital treatment for a minimum of 3 months. * presence of proteinuria levels at 1+ or higher during morning awakening or a urine protein quantity exceeding 30 mg/dl within the past 6 months (verified through medical records). * proficient communication skills in the thai language. * ownership of a telephone or device suitable for gaming and internet connectivity. * willingness and cooperation from both the family and the child to actively participate in the research. * discontinuation of steroid medication by school-age patients. exclusion criteria: * involve symptoms indicative of a critical condition, such as entering a crisis or severe complications like heart failure or pleural effusion. * school-age patients whose treatment plan has been modified by a physician, including the use of injectable medication instead of oral drugs or those receiving treatment in an inpatient setting.

Keywords: nephrotic syndrome proteinuria school-age children self-efficacy computer game